American Shared Hospital Services (AMS) Earnings Call Transcript & Summary

August 13, 2025

NYSE American US Health Care Health Care Providers and Services earnings 23 min

Earnings Call Speaker Segments

Kirin Smith

executive
#1

Megan, thank you, and I'm glad everyone could join us today. American Shared Hospital Services released its earnings press release for the second quarter of 2025 this morning prior to the market opening. If you'd like a copy, it's available on the company's website, www.ashs.com, under press releases in the investors tab. Before turning things over to management, I'd like to make a few remarks about forward-looking statements. Please note that anything said on this conference call about future expectations, plans, and prospects for the company counts as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. What we report could end up looking quite different from what these forward-looking statements suggest, and that can happen because of a range of significant factors — among them the ones covered in the documents the company files with the SEC. Those documents include the quarterly report on Form 10-Q covering the three months that closed on March 31, 2025, along with the annual report on Form 10-K for the year that ended on December 31, 2024. Nothing in this conference call is something the company promises to revise or refresh. Before handing things over to Ray, I want to go over how our Q&A works: every participant gets a chance at one question, plus one follow-up. And as we always do, we're glad to handle any extra questions outside of this call whenever you'd like. Thanks. At this point, I'll hand things off to our Executive Chairman, Ray Stachowiak. Go ahead, Ray.

Ray Stachowiak

executive
#2

Thanks, Kirin, and good afternoon to all of you. We appreciate your presence on today's call covering our second quarter 2025 earnings. I'll start things off with a few opening comments, and after that I'll pass things to our CEO, Gary Delanois, who will share more detail, and then to our CFO, Scott Frech, who will take you through a financial review of both our second quarter and first half 2025 results. Once our prepared remarks are done, we'll take your questions. It's a real pleasure to report that volumes keep getting better, and revenue for the second quarter of 2025 rose 16% on a sequential basis versus the prior quarter, powered by growth in our direct patient services segment along with further international business development initiatives. Benefits from our shift away from a focus on leasing cancer treatment equipment toward a service model centered more on patients keep showing up. I'm likewise glad to see treatment volumes carrying on their upward trend, and we're eager for a stronger back half of 2025. For those investors who think long term, I want to highlight that across the past four consecutive years, we've delivered meaningful revenue growth, nearly doubling since 2021, and we've been profitable for three years in a row. Investors should keep in mind that near term, normal fluctuations will occur given the particular character of our business, yet looking at the medium or longer term, we're positioned quite well to extend our record of strong, profitable revenue growth. My encouragement to investors is to keep their eyes on the long-term overall growth opportunity while we carry out our strategic initiatives and upcoming milestones. We've laid the groundwork for long-term outperformance as we pursue our growth strategy and strive to build substantial shareholder value. At this point I'll turn the call over to Gary and Scott, who will guide you through our overall business, our robust business development pipeline, exciting strategic growth opportunities, and an emphasis on operational and cost efficiencies that underpin our confidence in the company's long-term trajectory. With that, I'll pass the call to Gary Delanois for additional details.

Gary Delanois

executive
#3

Thank you, Ray, and hello to everyone this afternoon. Ray's excitement about the opportunities we have for growth, both near term and longer term, is something I share. My own belief and excitement regarding our strategy for growing the business keeps building, and the next phase of our growth has me enthusiastic. During the quarter just ended, we achieved sequential revenue growth in the double digits, up 16% versus the prior quarter. The continued gain from the Rhode Island acquisition we completed last year drove this growth, along with the launch of our new radiation therapy treatment center located in Puebla, Mexico. Even as we concentrate on growing revenue, profitability stays a key focus as well. Adjusted EBITDA for Q2 2025 reached $1.7 million, versus $949,000 in Q1 2025; strong cost controls remain in place on our end, and we depend on treatment volumes to fuel top-line growth. It is encouraging to watch treatment volume keep rising versus the prior quarter while we keep optimizing and expanding the business. Although quarterly swings in treatment volumes are something we do anticipate, the growth across the overall business energizes me, as do the business development initiatives we currently have underway. Benefits also keep flowing from our purchase of the three Rhode Island cancer treatment centers and our newer center in Puebla, Mexico. At those Rhode Island centers, working through our professional services agreement with Brown University Health, we have recruited and secured three exceptional radiation oncologists, and I am delighted to report that, as of today, they are conducting new patient consultations across our three centers. This major milestone is a crucial piece that lays the groundwork for rising volumes and utilization that will fuel future top and bottom line growth; we are making solid progress, and I stay confident that we will witness steady growth in treatment volumes plus greater engagement from referring physicians with the healthcare community and our health system partners, Care New England and Prospect CharterCare. Our radiation therapy equipment leasing segment also remains a focus, and we keep collaborating with our health system customers to build greater community awareness among referring physicians so that utilization of their Gamma Knife system, the gold standard for stereotactic radiosurgery, increases. A large growth opportunity also exists in our international business segment, where momentum keeps building. As you may remember, we operate the only Gamma Knife centers in Peru and Ecuador, and together with our third international center in Puebla, Mexico, we are treating cancer patients there for a full range of cancer diagnoses using the most advanced radiation therapy treatment capabilities available in our catchment area. Our fourth international center was established last year through our joint venture agreement for a Gamma Knife center in Guadalajara, Mexico, and our expectation remains that we will begin treating patients and producing revenue near the end of this year. Since this represents the sole S3 Gamma Knife available in a nation of 130 million, it will undoubtedly deliver substantial advantages to patients throughout Mexico and plainly serves as an unrealized expansion opportunity for our company. Throughout the coming months and years, we anticipate enhanced international expansion driven by greater treatment volumes in Ecuador, alongside robust case numbers from our recently upgraded facility in Peru plus our two additional locations in Guadalajara and Puebla. As we have mentioned on earlier calls, we are continuing to broaden our presence across Rhode Island. Purchasing a controlling stake in the three radiation therapy treatment centers located in Rhode Island marked our initial direct patient services cancer treatment centers within the United States. This business segment demonstrates the strength of our expansion approach while also showing our capacity to collaborate with health systems, Care New England, and Prospect CharterCare, which are the second and third largest health systems across Rhode Island. The second item is the Certificate of Need, or CON, which we have received to construct and run a fourth radiation therapy treatment center in Bristol, Rhode Island, and the third item is a CON that we formally secured this past December to construct and operate the state of Rhode Island's first proton beam radiation therapy center, representing yet another significant growth prospect. We are likewise continuing to assess possible tuck-in acquisitions that could assist in broadening our presence and contributing to our expansion. We anticipate sharing further specifics regarding these opportunities as they develop. Before passing the call to Scott, I want to restate our firm confidence in the business overall. Keep in mind that, like most growth stage companies, occasional fluctuations will occur. Our dedication and demonstrated history of long-term revenue growth and profitability, combined with our solid balance sheet, gives me tremendous confidence in the strategies we have established for long-term growth. With that said, I will now hand the call over to Scott Frech, our CFO, for a financial overview.

Scott Frech

executive
#4

Thanks, Gary, and good afternoon to all of you. For the three months that closed on June 30, 2025, we saw total revenue rise 16%, reaching $7.1 million, versus $6.1 million in Q1 2025, and it came in a bit higher than Q2 2024. Our direct patient services segment brought in $3.5 million during Q2 2025, up from $3.1 million in Q2 2024 — a 12% gain. That improvement came mainly from buying a majority stake in the Rhode Island radiation therapy operations during Q2 2024, along with kicking off operations in Puebla, Mexico, in the back half of 2024. Equipment leasing segment revenue fell to $3.6 million, down from $3.9 million in Q2 2024. Gamma Knife revenue climbed 25% over Q1 2025 to hit $2.6 million in Q2 2025, while slipping roughly 5% against Q2 2024. We performed 264 Gamma Knife procedures in Q2 2025 — a 27% jump from Q1 2025, yet 22% below Q2 2024. That drop stemmed largely from two contracts lapsing, one in December 2024 and the other in April 2025. Proton beam radiation therapy, or PBRT, revenue grew 17% from Q1 2025 to $1.9 million in Q2 2025, though it declined 20% versus Q2 2024. Total proton therapy fractions reached 1,114 in Q2 2025 — up 34% from Q1 2025 but down about 10% from Q2 2024. This decrease was mainly the result of ordinary cyclical swings. Linear accelerator, or LINAC, systems revenue rose 7% from Q1 2025 to $2.5 million in Q2 2025 and was 34% higher than Q2 2024, thanks to acquiring the Rhode Island radiation therapy operations and starting up operations in Puebla, Mexico. Our gross margin in Q2 2025 grew 73% from Q1 2025 to $1.6 million, but fell 34% against the $2.5 million recorded in Q2 2024. The year-over-year drop in gross margin percentage mirrors higher operational expenses, greater staffing costs, and technology infrastructure investments meant to support growth initiatives, plus reduced Gamma Knife treatment volumes and the robust margin growth from our direct patient services segment, which carries a lower gross margin percentage. Q2 2025 operating income showed a loss of $544,000, compared with a loss of $1.3 million in Q1 2025 and a loss of $1,000 in Q2 2024. Net loss attributable to American Shared Hospital Services for Q2 2025 came to $280,000, or $0.04 per diluted share, versus a net loss of $625,000 in Q1 2025, or $0.10 per share. Q2 2024 produced net income of $3.6 million, or $0.55 per diluted share. Adjusted EBITDA, our non-GAAP financial measure, stood at $1.7 million for Q2 2025, compared with $949,000 in Q1 2025 and $2 million in Q2 2024. Now I'll walk through our six-month results. During the first half of 2025, total revenue rose 7% to $13.2 million, compared with $12.3 million in the first half of 2024. Direct patient services brought in $6.6 million during the first half of 2025. That compares with $4.1 million in the same period of 2024 — a rise of 61%. The main forces behind this substantial expansion were the Rhode Island radiation therapy operations we acquired in Q2 2024, plus the start-up of our Puebla, Mexico operations in the second half of 2024. Equipment leasing revenue fell to $6.6 million, down from $8.2 million in the first half of 2024. Gamma Knife revenue came in at $4.7 million for the first half of 2025, a decline of 11.4%, versus $5.3 million in the first half of 2024. Gamma Knife procedures totaled 472 in the first half of 2025, which is 23% lower than the 613 procedures performed in the first half of 2024. The primary reasons for this drop were two contracts expiring — one in December 2024 and another in April 2025 — along with downtime needed to upgrade a third customer to newer technology. Proton beam radiation therapy, or PBRT, generated $3.6 million in the first half of 2025, down 30% from $5.1 million in the first half of 2024. Total proton therapy fractions reached 1,945 in the first half of 2025, a 23% decrease from 2,512 fractions in the first half of 2024; normal cyclical fluctuations were the main cause of this decline. Linear accelerator, or LINAC, systems revenue was $4.9 million for the first half of 2025, compared to $1.9 million in the first half of 2024, thanks to the Rhode Island radiation therapy operations acquisition and the launch of operations in Puebla, Mexico. Gross margin for the first half of 2025 stood at $2.6 million, versus $4.6 million in the first half of 2024. The percentage decline in gross margin reflects higher operational expenses, increased staffing costs, lower Gamma Knife treatment volumes, and the strong growth from our direct patient services segment, which carries a lower gross operating margin. An operating loss of $1.8 million was recorded for the first half of 2025, compared to a loss of $86,000 in the first half of 2024. Net loss attributable to American Shared Hospital Services for the first half of 2025 was $905,000, or $0.14 per diluted share, compared to net income of $3.7 million, or $0.57 per diluted share, for the first half of 2024. Adjusted EBITDA, our non-GAAP financial measure, came to $2.7 million for the first half of 2025, compared to $3.8 million for the first half of 2024. Now I'll move on to our balance sheet; we closed Q2 2025 in a strong financial position, backed by a solid balance sheet. As of June 30, 2025, cash and cash equivalents, including restricted cash, totaled $11.3 million, unchanged from $11.3 million at December 31, 2024. Shareholders' equity, excluding non-controlling interest, was $24.5 million, or $3.78 per outstanding share, compared to $25.2 million, or $3.92 per outstanding share, on December 31, 2024. For the second quarter of 2025, fully diluted weighted average common shares outstanding came to 6,582,000, versus 6,583,000 in the second quarter of 2024. That brings the formal portion of our presentation to a close. Thanks once more for being with us today. We're eager to share updates on how we're progressing in the quarters to come. At this point, I'll hand the call back to the operator and open the line for questions.

Marla Marin

analyst
#5

Thanks. With the growing focus on patients who come to you directly, you're posting impressive gains, and you're drawing on certain existing partnerships as well. You called out ties in Rhode Island with Brown University Health, plus what I believe were a few additional groups. With the two new Rhode Island sites coming, is there anything you can do before they open to help them get off to a fast start once the doors are open?

Gary Delanois

executive
#6

Yes, I am. I really appreciate your question. As I mentioned in my presentation, one of the main things we got done was bringing on three radiation oncologists working full time. Since we took over roughly a year ago, this marks the first occasion the team has been at full strength, and they will clearly be handling the new centers too. The Bristol site, a radiation therapy center, is of course the one coming up sooner. The proton center would be the project further out. Beyond that, as you noted, we're working with our health system partners — Care New England and Prospect CharterCare — plus Brown University Health, on delivering services, including additional ones, at those sites as well.

Marla Marin

analyst
#7

I'd assume the pair of additional centers stand to gain from that.

Gary Delanois

executive
#8

Would you mind saying that once more? Your audio cut out somewhat.

Marla Marin

analyst
#9

I was simply following up on that point; presumably, the 2 new centers will gain from it once they launch.

Gary Delanois

executive
#10

Correct. As we grow throughout the greater Rhode Island market, there are certainly scale efficiencies.

Marla Marin

analyst
#11

Okay, thank you.

Gary Delanois

executive
#12

Thank you.

Gary Delanois

executive
#13

Thanks, Megan, and I appreciate everyone being with us today. Let me close things out briefly and restate that we've reached a pivotal moment as we carry out our expansion plan. The foundational pieces are now in place, and we're intent on generating real momentum as that plan gains traction. Our strategy is something we believe in, and so is our team's capacity to deliver, and we're eager to share updates on our headway as we push forward with revenue growth, improved earnings, and enduring success. Should anything be unclear, feel free to get in touch. We're grateful once more for your interest in American Shared Hospital Services. Thanks to you. That brings the conference to a close.

Operator

operator
#14

That brings an end to our conference. We appreciate your joining us for today's presentation. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.